Enzastaurin Completed Phase 3 Trials for Diffuse Large B-Cell Lymphoma (DLBCL) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03263026Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™